DNA hypermethylation markers of poor outcome in laryngeal cancer

被引:0
作者
Josena K. Stephen
Kang Mei Chen
Veena Shah
Shaleta Havard
Alissa Kapke
Mei Lu
Michael S. Benninger
Maria J. Worsham
机构
[1] Henry Ford Hospital,Department of Otolaryngology/Head and Neck Surgery
[2] Henry Ford Hospital,Department of Pathology
[3] Henry Ford Hospital,Department of Biostatistics and Research Epidemiology
[4] Head and Neck Institute,undefined
[5] Cleveland Clinic,undefined
[6] American College of Medical Genetics,undefined
来源
Clinical Epigenetics | 2010年 / 1卷
关键词
Laryngeal cancer; Hypermethylation;
D O I
暂无
中图分类号
学科分类号
摘要
This study examined molecular (DNA hypermethylation), clinical, histopathological, demographical, smoking, and alcohol variables to assess diagnosis (early versus late stage) and prognosis (survival) outcomes in a retrospective primary laryngeal squamous cell carcinoma (LSCC) cohort. The study cohort of 79 primary LSCC was drawn from a multi-ethnic (37% African American), primary care patient population, diagnosed by surgical biopsies in the Henry Ford Health System from 1991 to 2004 and followed from 5 to 18 years (through 2009). Of the 41 variables, univariate risk factors of p < 0.10 were tested in multivariate models (logistic regression (diagnosis) and Cox (survival) models (p < 0.05)). Aberrant methylation of estrogen receptor 1 (ESR1; p = 0.01), race as African American (p = 0.04), and tumor necrosis (extensive; p = 0.02) were independent predictors of late stage LSCC. Independent predictors of poor survival included presence of vascular invasion (p = 0.0009), late stage disease (p = 0.03), and methylation of the hypermethylated in cancer 1 (HIC1) gene (p = 0.0002). Aberrant methylation of ESR1 and HIC1 signified independent markers of poorer outcome. In this multi-ethnic, primary LSCC cohort, race remained a predictor of late stage disease supporting disparate diagnosis outcomes for African American patients with LSCC.
引用
收藏
页码:61 / 69
页数:8
相关论文
共 374 条
[1]  
Arzimanoglou II(2002)Frequent LOH at hMLH1, a highly variable SNP in hMSH3, and negligible coding instability in ovarian cancer Anticancer Res 22 969-975
[2]  
Hansen LL(2000)DNA hypermethylation in tumorigenesis: epigenetics joins genetics Trends Genet 16 168-174
[3]  
Chong D(1998)Alterations in DNA methylation: a fundamental aspect of neoplasia Adv Cancer Res 72 141-196
[4]  
Li Z(2004)Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients Ann N Y Acad Sci 1022 40-43
[5]  
Psaroudi MC(1999)Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 21 103-107
[6]  
Dimitrakakis C(2000)Relationship between transcription and DNA methylation Curr Top Microbiol Immunol 249 75-86
[7]  
Jacovina AT(2004)Epigenetic and genetic loss of hic1 function accentuates the role of p53 in tumorigenesis Cancer Cell 6 387-398
[8]  
Shevchuk M(2005)Tumor suppressor hic1 directly regulates sirt1 to modulate p53-dependent DNA-damage responses Cell 123 437-448
[9]  
Reid L(2007)Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma Arch Otolaryngol Head Neck Surg 133 1131-1138
[10]  
Hajjar KA(2001)Methylation matters J Med Genet 38 285-303